Article Information
PubMed
Print ISSN
Online ISSN
History
- Published online June 14, 2022.
Article Versions
- You are currently viewing an Earlier version of this article (June 14, 2022 - 12:17).
- View the most recent version of this article
Copyright & Usage
© 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.
Author Information
- Jonathan N. Bauman1,
- Angela C. Doran2,
- Amanda King-Ahmad3,
- Raman Sharma4,
- Gregory S. Walker5,
- Jian Lin6,
- Tsung H Lin7,
- Jean-Baptiste Telliez7,
- Sakambari Tripathy8,
- Theunis C. Goosen9,
- Christopher Banfield8,
- Bimal K Malhotra8, and
- Martin E Dowty10,*
- 1PDM, Pfizer Global R&D, United States
- 2Medicine Design - ADME Sciences, Pfizer, United States
- 3Medicine Design, Pfizer Inc, United States
- 4PDM Biotransformation, Pfizer, United States
- 5PDM, Pfizer, United States
- 6PDM, Pfizer Inc, United States
- 7Inflammation and Immunology, Pfizer Inc, United States
- 8Clinical Pharmacology, Pfizer Inc, United States
- 9Pharmacokinetics, Dynamics & Metabolism, Pfizer, Inc, United States
- 10Pfizer Inc, United States
- ↵* Corresponding Author:
Martin E Dowty, Pfizer Inc, 1 Portland St, Cambridge, Massachusetts, 02139, United States. E-mail: martin.dowty{at}pfizer.com